STARKVILLE, Miss.—A Mississippi State professor of biological sciences is part of an interdisciplinary team of scientists throughout the U.S. advancing efforts to produce alternative forms of “greener ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility. The biotech is outlicensing ...

Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the ...

Maximizing opportunities for its proprietary ARCUS genome editing platform was among the priorities Precision BioSciences articulated last fall when it named veteran biotech executive Michael Amoroso ...

iECURE's ECUR-506 showed promising safety and efficacy in a Phase 1/2 study for neonatal-onset OTC deficiency, with no major safety issues. BMO Capital Markets upgraded Precision BioSciences to ...

- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - ...

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

A new prime editing sensor library targeting p53 mutations allowed scientists to interrogate thousands of tumor genotypes as they arose in endogenous contexts. Sánchez-Rivera and his team found that ...

Most genetic variants that contribute to disease are challenging to correct efficiently and without excess byproducts in therapeutically relevant cell types using programmable nucleases. In this ...

Genetic medicines in development for blood disorders include several therapies made by taking a patient’s cells and editing them outside of the body. Novartis is one of the companies testing this ...

Researchers explain how precision genome editing agents have enabled precise gene correction and disease rescue in inherited retinal diseases (IRDs). In a new paper, University of California, Irvine ...